Effect of cyclosporin analogues and FK506 on transcellular transport of daunorubicin and vinblastine via P-glycoprotein

Pharmaceutical Research

Volumn 13, Issue 7, 1996, Pages 1073-1077

  Tanaka, Kumiko ^a   Hirai, Midori ^a,c   Tanigawara, Yusuke ^a,d   Yasuhara, Masato ^a,e   Hori, Ryohei ^a,f   Ueda, Kazumitsu ^b   Inui, Ken Ichi ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c KOBE PHARMACEUTICAL UNIVERSITY   (Japan)

^d KOBE UNIVERSITY HOSPITAL   (Japan)

^e TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^f KINKI UNIVERSITY   (Japan)

Author keywords

Cyclosporine; Daunorubicin; FK506; P glycoprotein; Vinblastine

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOSPORIN; CYCLOSPORIN A; CYCLOSPORIN C; CYCLOSPORIN D; DAUNORUBICIN; DIHYDROCYCLOSPORIN A; DIHYDROCYCLOSPORIN C; GLYCOPROTEIN P; TACROLIMUS; UNCLASSIFIED DRUG; VALSPODAR; VINBLASTINE;

ANIMAL CELL; ARTICLE; CELL TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EFFECT; LIPOPHILICITY; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; SWINE;

ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL LINE; CHROMATOGRAPHY, THIN LAYER; CYCLOSPORINS; DAUNORUBICIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; P-GLYCOPROTEIN; TACROLIMUS; TRITIUM; VINBLASTINE;

EID: 0029739719     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016019010339     Document Type: Article

References (15)

1. I. B. Roninson (ed.). Molecular and cellular biology of multidrug resistance in tumor cells, Plenum Press, New York, 1991.
2. M. M. Gottesman and I. Pastan. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62:385-427 (1993).
3. M. Hirai, K. Tanaka, T. Shimizu, Y. Tanigawara, M. Yasuhara, R. Hori, Y. Kakehi, O. Yoshida, K. Ueda, T. Komano, and K. Inui. Cepharanthin, a multidrug resistant modifier, is a substrate for P-glycoprotein. J. Pharmacol. Exp. Ther. 275:73-78 (1995).
4. L. M. Slater, P. Sweet, M. Stupecky, and S. Gupta. Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. J. Clin. Invest. 77:1405-1408 (1986).
5. P. R. Twentyman. Cyclosporins as drug resistance modifiers. Biochem. Pharmacol. 43:109-117 (1992).
6. M. Naito, T. Oh-hara, A. Yamazaki, T. Danki, and T. Tsuruo. Reversal of multidrug resistance by an immunosuppressive agent FK506. Cancer Chemother. Pharmacol. 29:195-200 (1992).
7. 1). J. Pharmacol. Exp. Ther. 263:840-845 (1992).
8. P. M. Colombani, A. Robb, and A. D. Hess. Cyclosporin A binding to calmodulin: a possible site of action on T lymphocytes. Science 228:337-339 (1985).
9. V. F. J. Quesniaux, M. H. Schreier, R. M. Wenger, P. C. Hiestand, M. W. Harding, and M. H. V. Van Regenmortel. Cyclophilin binds to the region of cyclosporine involved in its immunosuppressive activity. Eur. J. Immunol. 17:1359-1365 (1987).
10. J. J. Siekierka, M. J. Staruch, S. H. Y. Hung, and N. H. Sigal. FK-506, a potent novel immunosuppressive agent, binds to a cytosolic protein which is distinct from the cyclosporin A-binding protein, cyclophilin. J Immunol. 143:1580-1583 (1989).
11. T. Hoof, A. Demmer, U. Christians, and B. Tümmler. Reversal of multidrug resistance in Chinese hamster ovary cells by the immunosuppressive agent rapamycin. Eur. J. Pharmacol. 246:53-58 (1993).
12. I. Tamai and A. R. Safa. Competitive interaction of cyclosporins with the vinca alkaloid-binding site of P-glycoprotein in multidrug resistant cells. J. Biol. Chem. 265:16509-16513 (1990).
13. T. Saeki, K. Ueda, Y. Tanigawara, R. Hori, and T. Komano. Human P-glycoprotein transports cyclosporin A and FK506. J. Biol. Chem. 268:6077-6080 (1993).
14. P. F. Augustijns, T. P. Bradshaw, L-S. L. Gan, R. W. Hendren, and D. R. Thakker. Evidence for a polarized efflux system in Caco2 cells capable of modulating cyclosporin A transport. Biochem. Biophys. Res. Comm. 197:360-365 (1993).
15. U. S. Rao and G. A. Scarborough. Direct demonstration of high affinity interactions of immunosuppressive drugs with the drug binding site of the human P-glycoprotein. Mol. Pharmacol. 45:773-776 (1994).